RxDoctor Payments Data

Yohan Lee, MD

Interventional Pain Medicine · Plainview, NYNPI 1992013528

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,606 of the $5,407 with a category attached, or 85.2%. 15 manufacturers reported payments, led by Boston Scientific at 25.1% of the total. 2025 is the largest year on record at $2,132, 2.4 times the $902 reported in 2019.

$5,407in general payments, 2019–2025

Across 145 payments — averaging $37.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Saluda Medical Americas, Inc.$1K
  • Scilex Pharmaceuticals Inc.$692
  • Medtronic$586
  • Relievant Medsystems, Inc.$348
  • AbbVie$244
  • plus $958 from 9 others

What the payments were for

  • Consulting fees$1252%
  • Travel & lodging$67613%
  • Food & beverage$4,60685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific40$1,357
Saluda Medical Americas, Inc.7$1,222
Scilex Pharmaceuticals Inc.36$692
Medtronic(2 entities)13$586
Relievant Medsystems, Inc.4$348
AbbVie(2 entities)12$244
Amgen9$234
Vertex7$176
Nalu Medical, Inc.2$142
Protega Pharmaceutials Inc8$142
Si-bone, Inc.2$93
Nevro Corp.2$63
Avanos Medical1$53
GRT US Holding, Inc.1$32
Forte Bio-pharma LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,407 in reported general payments places this provider in the 60th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$587,211
Medicare patients
624
Services billed
23,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen109$8,809
Gabapentin507$6,742
Pregabalin87$4,613
Lidocaine17$3,765
Duloxetine Hcl98$1,457
Tizanidine Hcl161$1,308
Diclofenac Sodium37$1,046
Amitriptyline Hcl93$898
Tramadol Hcl204$854
Calcitonin-SalmonCalcitonin,salmon,synthetic11$642
Celecoxib33$479
Baclofen24$402
Methylprednisolone59$341
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$312
Meloxicam76$307

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Plainview

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →